Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
This article was originally published in PharmAsia News
Executive Summary
Eisai has agreed to pay $325 million for Morphotek, a small biopharmaceutical company with proprietary discovery technologies and an oncology pipeline, the companies announced March 22. The deal is expected to close during Eisai's first quarter of 2007, which begins April 1
You may also be interested in...
Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals
Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals
Japanese Pharma, Hungry For Global Deals, Can Fill Gap Of Shrinking Partners - PharmAsia Summit
The deal appetite and the changing trend toward risk-sharing deals is making Japanese pharma attractive partners for U.S. biotechs, said a panel at Elsevier Business Intelligence's PharmAsia Summit in San Francisco.